Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

195.55USD
10:02am EDT
Change (% chg)

$-2.47 (-1.25%)
Prev Close
$198.02
Open
$196.30
Day's High
$197.88
Day's Low
$195.51
Volume
299,739
Avg. Vol
2,618,853
52-wk High
$210.19
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $133,059.70
Shares Outstanding(Mil.): 647.27
Dividend: 1.32
Yield (%): 2.57

Financials

  AMGN.O Industry Sector
P/E (TTM): 17.10 29.75 32.14
EPS (TTM): 12.02 -- --
ROI: 13.20 13.18 12.83
ROE: 36.30 15.14 14.95

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

Oct 16 2018

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON, Oct 16 Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

Oct 16 2018

UPDATE 1-AstraZeneca gets FDA breakthrough therapy label for asthma treatment

Sept 7 AstraZeneca Plc and Amgen Inc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for their drug to treat a type of severe asthma, potentially speeding up its development and regulatory review.

Sep 07 2018

AstraZeneca gets FDA breakthrough therapy label for asthma treatment

Sept 7 AstraZeneca Plc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for its drug to treat a type of severe asthma, potentially speeding up its development and review.

Sep 07 2018

Europe ready to cash in on cheap copies of AbbVie biotech drug

LONDON/NEW YORK U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market.

Aug 29 2018

FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug

LONDON/NEW YORK, Aug 29 U.S. drugmaker AbbVie faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market.

Aug 29 2018

UPDATE 3-Teva Pharm shares sink as sales forecast disappoints market

* Company still sees FDA approval of migraine drug mid-September

Aug 02 2018

Amgen profit beats Street view, will not raise prices again in 2018

Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

Jul 26 2018

UPDATE 2-Amgen profit beats Street view, will not raise prices again in 2018

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

Jul 26 2018

Amgen CEO says will not raise drug prices again this year

Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

Jul 26 2018

Earnings vs. Estimates